Open House Biologika Rabattverträge 2026 - 26 - Tralokinumab

This is an Open House procedure by Techniker Krankenkasse (TK) and affiliated health insurers to conclude discount agreements (Rabattverträge) for the active substance Tralokinumab, in accordance with § 130c SGB V. The procedure is open to all qualified pharmaceutical entrepreneurs who hold a valid marketing authorization for Tralokinumab. Contracts are offered on standardized, non-negotiable terms with no exclusivity. The contract duration is up to 24 months, starting 01 August 2026 and ending at the latest 31 July 2028. The procedure is not a public procurement under EU law; it remains continuously open for new participants throughout its validity. No estimated contract value, award criteria, or competitive selection are specified – eligible participants are automatically accepted upon confirming their eligibility. Documents are available but were not analyzed. Place of performance is throughout Germany.